Farah D, et al. - While it is usually not enough, initial treatment for type 2 diabetes mellitus is lifestyle change and metformin, so researchers compared the safety profiles of dipeptidyl peptidase-4 (DPP-4) inhibitors vs sulfonylureas in adult type 2 diabetes patients. Investigators found that DPP-4 inhibitors in combination with metformin had less overall adverse events, cardiovascular events, hypoglycemia, and severe hypoglycemic events. Data reported that the mean weight change difference was 1.92 kg in favor of DPP-4 inhibitors in combination with metformin vs sulfonylureas in combination with metformin. Findings revealed that DPP-4 inhibitor monotherapy also had lower hypoglycemia rates and severe hypoglycemic events and patients did not gain 1.19 kg. According to this systematic review and meta-analysis, better safety was seen with DPP-4 inhibitors vs sulfonylureas for both comparisons; it is more prominent when metformin is included in the treatment regimen.